Academic Journals Database
Disseminating quality controlled scientific knowledge

Potential Opponent for 18FDG: Gd3+-DTPA-DG: A New Synthetic MRI Contrast Agent

ADD TO MY LIST
 
Author(s): Mehdi Shafiee Ardestani

Journal: Iranian Journal of Radiology
ISSN 1735-1065

Volume: 7;
Issue: S1;
Start page: 56;
Date: 2010;
Original page

Keywords: keyword

ABSTRACT
Glucose mediated imaging tools have recently be-come an area of research interest in the field of nuclear medicine, especially Positron Emission Tomography (PET) imaging. The difficulties in the use, preparation and cost of radioactively-labeled glycosylated compounds led to the research and development in this present study of a new gadolinium-labeled glucose that does not have a radioactive half-life or difficulties in its synthesis and utilization. Based on the structure of fluorodeoxyglucose (18FDG), a new compound consisting of a D-glucose conjugated to a well-known chelator DTPA was synthesized, labeled with Gd3+ and examined in vitro and in vivo. The results showed a good anti-cancer potency for the prepared complex. Gd3+ -DTPA-DG did not produce any significant alteration in the blood glucose level and was also phosphorylated by hexokinase enzyme. In vitro relaxation times T1 and T2 were determined and compared with a standard compound Magnevist®. Finally, imaging studies were performed in tumor-bearing mice and the tumor areas were shown successfully. This compound may have great potential in the future in radio-oncology.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?